AUTHORS
Hemavathi Baskarane, MD DM, Ashlee Joseph, BS2, Suheil Albert Atallah-Yunes, MD3, Alexander P. Boardman, MD4, Kevin David, MD5, Zachary Epstein-Peterson, MD6, Lorenzo Falchi, MD7, Paola Ghione, MD, MS8, Steven Horwitz, M.D.9, Andrew Intlekofer, MD, DPhil10, Jennifer Kimberly Lue, M.D.11, Efrat Luttwak, Luttwak, MD12, Alison Moskowitz, MD13, Ariela Noy, MD14, Colette Owens, MD15, Maria Lia Palomba, MD16, Mark Roschewski, MD17, Gilles Salles I, MD, PhD18, Quinlan Sievers, MD, PhD19, Raphael Steiner, MD20, Robert Stuver, MD21, Santosha Vardhana, MD, PhD22, Jasmine Zain, M.D.23, Andrew Zelenetz, MD24, Anita Kumar, MD25, Paul Hamlin, MD26, Pallawi Torka, MD27
AFFILIATIONS
1 Memorial Sloan Kettering Cancer Center, New York, United States
2 Memorial Sloan Kettering Cancer Center, New York, United States
3 Memorial Sloan Kettering Cancer Center, New York, United States
4 Memorial Sloan Kettering Cancer Center, New York, United States
5 Memorial Sloan Kettering Cancer Center, New York, United States
6 Memorial Sloan Kettering Cancer Center, New York, United States, Memorial Sloan Kettering Cancer Center, New York, United States
7 Memorial Sloan Kettering Cancer Center, New York, United States
8 Memorial Sloan Kettering Cancer Center, New York, United States
9 Memorial Sloan Kettering Cancer Center, New York, United States
10 Memorial Sloan Kettering Cancer Center, New York, United States
11 Memorial Sloan Kettering Cancer Center, New York, United States
12 Memorial Sloan Kettering Cancer Center, New York, United States
13 Memorial Sloan Kettering Cancer Center, New York, United States
14 Memorial Sloan Kettering Cancer Center, New York, United States
15 Memorial Sloan Kettering Cancer Center, New York, United States
16 Memorial Sloan Kettering Cancer Center, New York, United States
17 Memorial Sloan Kettering Cancer Center, New York, United States
18 Memorial Sloan Kettering Cancer Center, New York, United States
19 Memorial Sloan Kettering Cancer Center, New York, United States
20 Memorial Sloan Kettering Cancer Center, New York, United States
21 Memorial Sloan Kettering Cancer Center, New York, United States
22 Memorial Sloan Kettering Cancer Center, New York, United States
23 Memorial Sloan Kettering Cancer Center, New York, United States
24 Memorial Sloan Kettering Cancer Center, New York, United States
25 Memorial Sloan Kettering Cancer Center, New York, United States
26 Memorial Sloan Kettering Cancer Center, New York, United States
27 Memorial Sloan Kettering Cancer Center, New York, United States
ABSTRACT
Background
Female sex is associated with superior outcomes across most lymphoma subtypes, but its independent prognostic impact in mantle cell lymphoma (MCL) remains unclear. Given known sex-based differences in rituximab pharmacokinetics, immune function, and MCL incidence, we evaluated the association between sex, clinical characteristics, treatment, and outcomes in older adults (OA) with MCL.
Methods
Patients aged ≥60 years diagnosed with MCL and treated at Memorial Sloan Kettering Cancer Center between 2000 and 2025 were included. The age cutoff was selected to minimize potential confounding by endogenous estrogen exposure. Baseline characteristics, treatment patterns, and outcomes were compared between women and men. Lugano criteria were used for response adjudication using PET-CT; bone marrow biopsy and endoscopy data were utilized when available. Impact of gender and other baseline characteristics on duration of response, progression-free survival (PFS) and overall survival (OS) were evaluated using univariable and multivariable analyses.
Results
Among 538 patients (median age, 70 years [range 60-102]), 74% were men. Women were older at diagnosis (median 71 vs 70 years; p=0.028), more frequently aged ≥80 years (22% vs 12%; p=0.008), and more likely to have elevated LDH (34% vs 25%; p=0.040). Other disease characteristics, including MIPI risk group, blastoid/pleomorphic morphology, Ki-67, TP53 alterations, and 17p deletion were similar between the sexes.
Women were more frequently managed with initial observation than men (50/139 [36%] vs. 98/399 [25%]; p=0.009). SOX11 testing was available in 60 of 148 patients (41%) managed with initial observation. Among those tested, SOX11 positivity was similar between men (26/37, 70%) and women (17/23, 74%; p=0.8).
The most common first-line (1L) treatment approaches included intensive chemoimmunotherapy with planned autologous stem cell transplantation (ASCT) (38%; cytarabine-based regimens or R-CHOP/R-ICE), bendamustine-based regimens (26%), and CHOP-based regimens (11%). Overall, 26% of patients were enrolled in clinical trials, 27% underwent ASCT, and 25% received rituximab maintenance. Treatment selection and first-line response rates were similar between women and men, including overall response (77% vs 77%) and complete response (64% vs 64%; both p>0.9). After a median follow up of 8.3 years (similar in women and men, p=0.2), women demonstrated a trend toward longer median duration of response (6.1 vs 4.1 years; p=0.08) and lower relapse rates after first-line therapy (47% vs 56%; p=0.08).
Women experienced significantly longer median PFS (4.9 vs 3.4 years; p=0.008) and OS (9.6 vs 7.1 years; p=0.013). This survival advantage was not observed among patients receiving rituximab maintenance, with similar PFS (6.4 vs 5.8 years) and OS (14.0 vs 13.0 years) between women and men.
On univariable analysis, increasing age, male sex, ECOG performance status ≥2, high-risk MIPI, Ki-67 ≥50%, elevated LDH, non-receipt of intensive chemoimmunotherapy, omission of rituximab maintenance, and autologous stem cell transplantation were associated with inferior PFS and OS. SOX11 expression was not significant after multiple-testing correction (q=0.26). On multivariable analysis, female sex remained independently associated with improved PFS (HR, 0.50; 95% CI, 0.34–0.74; p<0.001) and OS (HR, 0.41; 95% CI, 0.26–0.66; p<0.001). Increasing age, poor ECOG performance status, and Ki-67 ≥50% independently predicted inferior PFS and OS, whereas intensive chemoimmunotherapy independently improved PFS (HR, 0.49; 95% CI, 0.32–0.76; p=0.006).
Conclusions
Female sex was independently associated with superior PFS and OS in older adults with MCL despite similar disease biology, treatment selection, and initial response rates. The absence of a sex-based survival difference among patients receiving rituximab maintenance suggests that maintenance therapy may attenuate this disparity, although this subgroup was small. These findings support sex as an independent prognostic factor in older adults. The observed survival advantage is not fully explained by baseline clinical or treatment-related factors and warrants investigation into the biological and pharmacologic mechanisms underlying these differences.
DISCLOSURES
Hemavathi Baskarane, MD DM: No relevant conflicts of interest to declare.